NDAOPHTHALMICSOLUTION/DROPS
Approved
May 2025
Lifecycle
Launch
Competitive Pressure
0/100
Data completeness
2/8 — Basic
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRYPTYR (acoltremon) is a newly approved ophthalmic solution administered as eye drops for an undisclosed indication. The mechanism of action and pharmacologic class have not been disclosed in available data. This is an Alcon-sponsored NDA that entered the market in May 2025.
Launch16.6 years to LOE
Early-stage launch with no current competitive pressure creates opportunity for commercial team expansion and market-building initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
TRYPTYR represents a fresh launch opportunity for pharma professionals seeking to build a brand from market entry. The extended patent protection (16.7 years) and unopposed competitive landscape create favorable conditions for career growth in commercial, medical, and market access functions.
Brand ManagerField Sales Representative
Worked on TRYPTYR at Alcon? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.